New pill takes aim at hard-to-treat cancers with NRAS mutation

NCT ID NCT07170293

Recruiting now Disease control Sponsor: Tianjin Medical University Second Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests an experimental drug called tunlametinib in 15 people with advanced solid tumors (not melanoma) that have a mutation in the NRAS gene and have not responded to other treatments. The drug is taken as a capsule twice a day in 21-day cycles. The main goal is to see if the drug can shrink tumors, and researchers will also track how long any benefit lasts and monitor for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tunlametinib (a targeted cancer drug taken as a capsule)
What this could lead to: If it works, this could point toward a new treatment option for people with certain hard-to-treat cancers that have an NRAS mutation.
What could go wrong: This is a very small early-phase trial with only 15 people, so results may not apply broadly. The drug may not shrink tumors or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID CANCERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID CANCERS

Contacts and locations

Locations

Tianjin Medical Unversity Second Hospital
RECRUITING

Tianjin, Tianjin Municipality, 300211, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.